BIOCRYST PHARMACEUTICALS INC
BCRXNasdaqHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $874.8M | $450.7M | $331.4M | $270.8M | $157.2M | $17.8M |
| Operating income | $341.0M | −$2.5M | −$103.7M | −$148.4M | −$177.7M | −$174.8M |
| Net income | $263.9M | −$88.9M | −$226.5M | −$247.1M | −$184.1M | −$182.8M |
| Total assets | $514.2M | $490.4M | $517.0M | $550.0M | $588.2M | $334.7M |
| Total liabilities | $633.3M | $966.4M | $972.5M | — | — | — |
| Equity | −$119.2M | −$475.9M | −$455.5M | −$294.6M | −$107.0M | −$19.3M |
| EPS (diluted) | $1.21 | $-0.43 | $-1.18 | $-1.33 | $-1.03 | $-1.09 |
| Shares out. | 209.0M | 206.1M | 188.5M | 184.7M | 177.2M | 154.2M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- 39.0%
- Net margin
- 30.2%
- Return on equity
- −221.4%
- Return on assets
- 51.3%
- Return on capital (ROCE)
- 107.2%
- Liabilities / assets
- 123.2%
- Debt / equity
- —
- Book value / share
- $-0.57
- Revenue growth (YoY)
- 94.1%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -2.63distress
- Accruals / assets
- −16.2%clean
- Beneish M-Score
- -2.27normal
- Piotroski F-Score
- 7/9strong
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 1 warning● 4 good- Negative shareholder equity
- Altman Z″ in the distress zone
- High leverage (liabilities > 70% of assets)
- Operating margin is positive
- Revenue is growing year-over-year
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
FDA-approved drugs
openFDA · most recent- ORLADEYODec 3, 2020
- RAPIVABDec 19, 2014
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 3Active Not Recruitingreadout ~2024-09-11Berotralstat Treatment in Children With Hereditary Angioedema
- Phase 1Recruitingreadout ~2026-10A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725
- Phase 3Enrolling By Invitationreadout ~2031-08Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- State Street CorpPassive (13G)May 12, 2026
- Vanguard Capital Management LlcPassive (13G)Apr 29, 2026
- Vanguard Group IncPassive (13G)Mar 26, 2026
- Flynn James EPassive (13G)Feb 12, 2026
- Ra Capital Management, L.P.Passive (13G)Nov 12, 2025
- Avoro Capital Advisors LlcPassive (13G)May 15, 2025
- Blackrock, Inc.Passive (13G)Apr 17, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Stonehouse Jon PDirector | Feb 27, 2026 | Grant | 421 | $8.75 |
| Milano VincentDirector | Feb 27, 2026 | Grant | 848 | $8.75 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 36.1M | 6.1 | -3.5% |
| Apr 30, 2026 | 37.4M | 11.1 | -2.9% |
| Apr 15, 2026 | 38.5M | 8.0 | +9.5% |
| Mar 31, 2026 | 35.2M | 4.2 | -6.1% |
| Mar 13, 2026 | 37.5M | 7.7 | -7.3% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operations · Regulation FD disclosureMay 6, 2026
- Regulation FD disclosureMay 4, 2026
- Results of operations · Regulation FD disclosureFeb 26, 2026
- Entered a material agreement · Completed an acquisition or disposition · New financial obligation · Regulation FD disclosureJan 23, 2026
- Results of operations · Regulation FD disclosure · Other material eventJan 12, 2026
- Regulation FD disclosureJan 9, 2026
- Other material eventDec 12, 2025
- Director / officer changeDec 11, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 4PRIMARY DOCUMENTMay 19, 2026
- 144May 18, 2026
- 4PRIMARY DOCUMENTMay 15, 2026
- 144May 13, 2026
- SCHEDULE 13GMay 12, 2026
- 10-QMay 6, 2026
- 8-KFORM 8-KMay 6, 2026
- 8-KFORM 8-KMay 4, 2026
- SCHEDULE 13GApr 29, 2026
- ARSApr 23, 2026
- DEFA14AApr 23, 2026
- DEF 14AApr 23, 2026
- 4PRIMARY DOCUMENTApr 7, 2026
- 3Apr 7, 2026
- SCHEDULE 13G/AMar 26, 2026
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.